5-year overall survival rates of childhood cancer in mainland France over 2000-2016, by diagnostic and age groups. |
|||||||||
< 1 year |
1-4 years |
5-9 years |
10-14 years |
||||||
Diagnostic groups and subgroups |
|||||||||
I. Leukemias, myeloproliferative diseases, and myelodysplastic diseases |
61.2 |
[56.6-65.5] |
89.9 |
[88.8-90.8] |
89.2 |
[87.9-90.4] |
80.8 |
[78.8-82.5] |
** |
I.a Lymphoid leukemias |
53.8 |
[46.4-60.7] |
93.8 |
[92.9-94.6] |
91.4 |
[90.1-92.6] |
84.0 |
[81.9-86] |
** |
I.b Acute myeloid leukemias |
66.1 |
[58.9-72.4] |
66.9 |
[61.9-71.3] |
80.8 |
[75.6-85.1] |
67.6 |
[62.4-72.3] |
** |
II. Lymphomas and reticuloendothelial neoplasms |
92.9 |
[59.1-99.0] |
92.5 |
[89.3-94.8] |
94.4 |
[92.7-95.7] |
94.7 |
[93.5-95.6] |
|
II.a Hodgkin lymphomas |
- |
- |
100.0 |
- |
98.6 |
[96.3-99.5] |
97.4 |
[96.3-98.2] |
|
II.b Non-Hodgkin lymphomas (except Burkitt lymphomas) |
90.9 |
[50.8-98.7] |
86.4 |
[79.9-90.9] |
89.9 |
[85.9-92.7] |
90.3 |
[87.2-92.7] |
|
II.c Burkitt lymphomas |
100.0 |
- |
96.0 |
[91.8-98.1] |
95.1 |
[92.3-96.9] |
90.4 |
[85.6-93.6] |
|
III. CNS and miscellaneous intracranial and intraspinal neoplasms |
62.7 |
[58.2-66.9] |
72.9 |
[71-74.6] |
72.4 |
[70.6-74.2] |
81.4 |
[79.7-83.1] |
** |
III.a Ependymomas and choroid plexus tumors |
70.5 |
[60.3-78.5] |
67.9 |
[62.1-72.9] |
79.9 |
[72.2-85.6] |
86.9 |
[79.7-91.6] |
** |
III.b Astrocytomas |
82.5 |
[75.1-87.8] |
94.3 |
[92.6-95.5] |
82.9 |
[80.3-85.3] |
82.5 |
[79.4-85.1] |
** |
III.c Intracranial and intraspinal embryonal tumors |
26.1 |
[18.7-34.1] |
38.1 |
[33.8-42.3] |
69.1 |
[64.6-73.1] |
79.1 |
[73.3-83.8] |
** |
III.d Other gliomas |
67.2 |
[50.3-79.5] |
44.5 |
[38.2-50.5] |
26.2 |
[22.0-30.6] |
47.0 |
[41.3-52.6] |
** |
III.e Other specified intracranial and intraspinal neoplasms |
84.2 |
[71.9-91.5] |
94.2 |
[90.5-96.5] |
95.6 |
[93.2-97.1] |
96.7 |
[94.9-97.8] |
** |
IV. Neuroblastomas and other peripheral nervous cell tumors |
90.7 |
[88.6-92.4] |
67.2 |
[64.3-70.0] |
66.1 |
[59.7-71.8] |
71.4 |
[60.0-80.0] |
** |
IV.a Neuroblastomas and ganglioneuroblastomas |
90.7 |
[88.7-92.5] |
67.1 |
[64.2-69.9] |
66.2 |
[59.7-71.9] |
62.8 |
[49.4-73.6] |
** |
V. Retinoblastomas |
99.5 |
[97.9-99.9] |
99.0 |
[97.5-99.6] |
100.0 |
- |
100.0 |
- |
|
VI. Renal tumors |
88.3 |
[83.5-91.9] |
94.3 |
[92.7-95.6] |
93.2 |
[89.8-95.5] |
81.9 |
[70.3-89.3] |
** |
VI.a Nephroblastomas and other nonepithelial renal tumors |
88.3 |
[83.5-91.9] |
94.3 |
[92.7-95.6] |
93.3 |
[89.8-95.6] |
85.0 |
[69.6-93.0] |
** |
VII. Hepatic tumors |
89.9 |
[80.8-94.8] |
87.3 |
[80.8-91.7] |
74.4 |
[55.0-86.4] |
62.4 |
[45.5-75.4] |
** |
VII.a Hepatoblastomas |
89.7 |
[80.5-94.7] |
87.5 |
[80.8-91.9] |
74.6 |
[51.9-87.7] |
44.4 |
[13.6-71.9] |
** |
VIII. Malignant bone tumors |
85.7 |
[33.4-97.9] |
74.2 |
[63.2-82.4] |
75.2 |
[70.5-79.2] |
73.6 |
[70.5-76.4] |
|
VIII.a Osteosarcomas |
100.0 |
- |
57.1 |
[28.4-78.0] |
71.1 |
[63.4-77.4] |
71.7 |
[67.2-75.7] |
|
VIII.c Ewing tumors and related bone sarcomas |
80.0 |
[20.4-96.9] |
78.4 |
[65.6-86.9] |
77.4 |
[70.7-82.7] |
73.9 |
[68.9-78.2] |
|
IX. Soft tissue and other extraosseous sarcomas |
69.8 |
[62.9-75.8] |
75.2 |
[71.4-78.5] |
75.3 |
[71.2-78.9] |
68.2 |
[64.1-72.0] |
** |
IX.a Rhabdomyosarcomas |
84.6 |
[73.3-91.4] |
76.3 |
[71.9-80.0] |
72.9 |
[67.5-77.6] |
60.8 |
[53.1-67.6] |
** |
IX.b Fibrosarcomas, peripheral nerve sheath tumors, and other fibrous neoplasms |
88.7 |
[76.5-94.7] |
91.7 |
[53.9-98.8] |
82.6 |
[60.0-93.1] |
67.2 |
[50.7-79.3] |
|
IX.d Other specified soft tissue sarcomas |
39.0 |
[26.7-51.1] |
72.7 |
[63.0-80.3] |
79.2 |
[71.3-85.2] |
72.6 |
[66.8-77.6] |
** |
IX.e Unspecified soft tissue sarcomas |
56.3 |
[29.5-76.2] |
49.7 |
[27.4-68.5] |
74.5 |
[56.4-85.9] |
71.0 |
[57.8-80.7] |
|
X. Germ-cell tumors, trophoblastic tumors, and neoplasms of gonads |
91.3 |
[87.1-94.2] |
96.3 |
[92.7-98.1] |
96.9 |
[92.6-98.7] |
93.5 |
[90.7-95.4] |
* |
X.a Intracranial and intraspinal germ cell tumors |
91.6 |
[76.1-97.2] |
93.4 |
[84.8-97.2] |
95.6 |
[88.6-98.3] |
94.5 |
[90.3-96.9] |
|
X.b Malignant extracranial and extragonadal germ cell tumors |
89.1 |
[83.5-92.9] |
96.2 |
[88.6-98.8] |
100.0 |
- |
85.7 |
[66.1-94.4] |
|
X.c Malignant gonadal germ cell tumors |
100.0 |
- |
100.0 |
- |
100.0 |
- |
96.0 |
[92.1-98.0] |
|
XI. Other malignant epithelial neoplasms and malignant melanomas |
96.9 |
[79.8-99.6] |
87.5 |
[79.0-92.7] |
93.1 |
[88.6-95.8] |
94.0 |
[91.8-95.6] |
|
XI.b Thyroid carcinomas |
100.0 |
- |
100.0 |
- |
98.8 |
[91.5-99.8] |
98.9 |
[96.6-99.6] |
|
XI.d Malignant melanomas |
100.0 |
- |
81.0 |
[62.5-91.0] |
89.3 |
[76.2-95.4] |
88.3 |
[79.9-93.4] |
|
XII. Other and unspecified malignant neoplasms |
100.0 |
- |
76.5 |
[58.4-87.5] |
85.7 |
[33.4-97.9] |
58.6 |
[26.7-80.6] |
|
All cancers (excluding Langherhans cell histiocytosis) |
81.3 |
[79.9-82.7] |
83.3 |
[82.6-84.1] |
82.6 |
[81.7-83.4] |
83.7 |
[82.9-84.5] |
** |
Langherhans cell histiocytosis |
87.2 |
[73.8-94.1] |
96.4 |
[86.2-99.1] |
100.0 |
- |
100.0 |
- |
|
All cancers (including Langherhans cell histiocytosis) |
81.4 |
[80.0-82.8] |
83.4 |
[82.7-84.1] |
82.6 |
[81.7-83.4] |
83.8 |
[82.9-84.6] |
** |
** pvalue <0.01; * pvalue < 0.05 |
|||||||||